Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy

Supportive Care in Cancer

Volumn 20, Issue 12, 2012, Pages 3241-3246

  Lorusso, Vito ^a   Giampaglia, Marianna ^a   Petrucelli, Luciana ^a   Saracino, Valeria ^a   Perrone, Tania ^b   Gnoni, Antonio ^a  

^a VITO FAZZI HOSPITAL   (Italy)

^b Scientific Department   (Italy)

Author keywords

Chemotherapy induced nausea and vomiting (CINV); Food intake; Multiple cycles; Multiple day chemotherapy; Palonosetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; EPIRUBICIN; IFOSFAMIDE; PACLITAXEL; PALONOSETRON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MASS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOOD INTAKE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NUTRITIONAL STATUS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 84868469037     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1469-9     Document Type: Article

References (31)

1. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482-2494
2. De Wit R, Van Den Berg H, Burghouts J et al (1998) Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Brit J Cancer 77(9):1487-1491
3. Sigsgaard T, Herrstedt J, Handberg J et al (2001) Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 19(7):2091-2097
4. De Wit R, Herrstedt J, Rapoport B et al (2003) Addition of the oral NK 1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105-4111
5. Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E (2008) Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 94:447-452
6. NavariRM (2007) Prevention of emesis from multiple-day and highdose chemotherapy regimens. J Natl Compr CancerNetw5(1):51-59
7. Saito M, Tsukuda M (2010) Review of palonosetron: emerging data distinguishing it as a novel 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 11(6):1003-1014
8. Antiemesis (2011) NCCN clinical practice guidelines in oncology. V.3. 2011. Available from: http://www.nccn.org/professionals/physician-gls/pdf/ antiemesis.pdf [last accessed 4 May 2011]
9. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232-v243
10. Eisenberg P, Figuero-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist. Results of a phase III, single dose trial versus dolasetron. Cancer 98(11):2473-2482
11. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577
12. Rubenstein EB, Gralla RJ, Eisenberg P (2003) Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Combined results of two phase III trials. Proc Am Soc Clin Oncol 22:729-932
13. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441-1449
14. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115-124
15. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822-2830
16. Khojasteh A, Khojasteh A, Thornburg BG et al (2009) Casopitant: a new warrior in the antiemetic crusade. Expert Opin Pharmacother 10 (8):1367-1376
17. Lorusso V, Spedicato A, Petrucelli L et al (2009) Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer 17(12):1469-1473
18. Cartmell AD, Ferguson S, Yanagihara R et al (2003) Protection against chemotherapy-induced nausea and vomiting (CINV) is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron (PALO), a potent 5-HT3 receptor antagonist (RA). Proc Am Soc Clin Oncol 22: 2003 (abstr 3041))
19. Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S et al (1999) Perception of chemotherapy side effects cancer versus non cancer patients. Cancer Pract 7:59-65
20. Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:10
21. Einhorn LH, Brames MJ, Dreicer R et al (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293-1300
22. Rozzi A, Nardoni CA, Corona M et al (2009) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 19:697-701
23. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F et al (2009) Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receivingmultiple- day chemotherapy. Support Care Cancer 17(2):205-209
24. Aapro M, Fabi A, Nolè F et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol May 21 (5):1083-1088, Epub 2010 Jan 15
25. Celio L, Frustaci S, Denaro A, et al (2010 June 25) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19:1217-1225
26. Vardy J, Chiew KS, Galica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011-1015
27. Rubenstein EB (1994) Costs and benefits of outpatient therapy. Support Care Cancer 2(5):307-311
28. Stoltz R, Cyong JC, Shah A et al (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 44:520-531
29. Wong EH, Clark R, Leung E et al (1995) The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114(4):851-859
30. Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469-478
31. Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5- HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626(2-3):193-199